Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTXNASDAQ:CYCCNASDAQ:OTLKNASDAQ:QNTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$4.78-2.0%$6.68$4.15▼$17.49$51.01M0.7253,793 shs23,025 shsCYCCCyclacel Pharmaceuticals$0.28+21.6%$0.28$0.17▼$4.00$57.74M0.151.23 million shs3.72 million shsOTLKOutlook Therapeutics$1.53-1.3%$1.42$0.87▼$9.29$48.99M0.47735,195 shs213,282 shsQNTMQuantum Biopharma$7.08+2.5%$6.25$2.70▼$18.00$13.59M0.371.10 million shs49,757 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics-1.41%+10.66%-42.86%-35.28%-65.63%CYCCCyclacel Pharmaceuticals-0.52%+1.28%-23.67%-38.27%-89.96%OTLKOutlook Therapeutics0.00%+6.90%+10.71%-22.11%-81.10%QNTMQuantum Biopharma+0.58%+9.68%+17.92%+111.96%+690,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo Therapeutics3.1108 of 5 stars4.43.00.00.00.81.71.3CYCCCyclacel Pharmaceuticals2.5135 of 5 stars3.33.00.00.02.52.50.6OTLKOutlook Therapeutics1.3305 of 5 stars3.42.00.00.01.10.00.6QNTMQuantum BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 2.83Moderate Buy$33.00590.38% UpsideCYCCCyclacel Pharmaceuticals 2.50Moderate Buy$11.003,849.73% UpsideOTLKOutlook Therapeutics 2.80Moderate Buy$10.20566.67% UpsideQNTMQuantum Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest QNTM, OTLK, AVTX, and CYCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025AVTXAvalo TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform ➝ Buy$23.003/25/2025AVTXAvalo TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.003/20/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/20/2025AVTXAvalo TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$18.002/28/2025AVTXAvalo TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$48.002/24/2025OTLKOutlook TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$33.00 ➝ $24.002/21/2025AVTXAvalo TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$18.002/20/2025AVTXAvalo TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/18/2025OTLKOutlook TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.002/18/2025OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $3.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$441K115.67N/AN/A$9.11 per share0.52CYCCCyclacel Pharmaceuticals$74K780.31N/AN/A$0.57 per share0.49OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.57) per shareN/AQNTMQuantum BiopharmaN/AN/AN/AN/A$21.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$31.54MN/A0.00N/AN/AN/A-442.16%122.99%5/12/2025 (Estimated)CYCCCyclacel Pharmaceuticals-$22.56M-$3.50N/A∞N/A-18,150.00%-1,901.11%-188.23%5/7/2025 (Estimated)OTLKOutlook Therapeutics-$75.37M-$7.42N/AN/AN/AN/AN/A-225.12%5/21/2025 (Estimated)QNTMQuantum Biopharma-$17.90M-$15.70N/AN/AN/AN/A-84.21%-62.63%5/13/2025 (Estimated)Latest QNTM, OTLK, AVTX, and CYCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q2 2025OTLKOutlook Therapeutics-$0.55N/AN/AN/AN/AN/A5/13/2025N/AQNTMQuantum Biopharma-$0.37N/AN/AN/AN/AN/A5/12/2025Q4 2024AVTXAvalo Therapeutics-$1.07N/AN/AN/AN/AN/A5/7/2025Q1 2025CYCCCyclacel Pharmaceuticals-$0.29N/AN/AN/A$0.03 millionN/A4/2/2025Q4 2024CYCCCyclacel Pharmaceuticals-$0.29-$0.33-$0.04-$0.33$0.01 million$0.01 million3/28/2025Q4 2024QNTMQuantum Biopharma-$0.80-$2.89-$2.09-$2.89$0.92 millionN/A2/14/2025Q1 2025OTLKOutlook Therapeutics-$0.85-$0.89-$0.04$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ACYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ALatest QNTM, OTLK, AVTX, and CYCC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/24/2025CYCCCyclacel Pharmaceuticals$0.154/29/20254/29/20255/1/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A1.421.42CYCCCyclacel PharmaceuticalsN/A0.770.77OTLKOutlook TherapeuticsN/A0.320.64QNTMQuantum BiopharmaN/A3.763.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%CYCCCyclacel Pharmaceuticals23.58%OTLKOutlook Therapeutics11.20%QNTMQuantum Biopharma1.24%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics0.25%CYCCCyclacel Pharmaceuticals68.00%OTLKOutlook Therapeutics4.80%QNTMQuantum Biopharma8.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4010.67 million10.37 millionNot OptionableCYCCCyclacel Pharmaceuticals14207.34 million4.78 millionOptionableOTLKOutlook Therapeutics2032.02 million30.48 millionOptionableQNTMQuantum BiopharmaN/A1.92 million1.76 millionN/AQNTM, OTLK, AVTX, and CYCC HeadlinesRecent News About These CompaniesQuantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern TimeApril 24 at 7:00 AM | globenewswire.comQuantum BioPharma adds Kevin Malone as advisorApril 24 at 2:40 AM | uk.investing.comQuantum Group appoints Malone as advisor to Board of DirectorsApril 23 at 7:27 AM | markets.businessinsider.comQuantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board AdvisorApril 22 at 7:00 AM | globenewswire.comQuantum BioPharma Corporate UpdateApril 18, 2025 | newsfilecorp.comQuantum Group wins reconsideration motion by Dr. Bokhari at CoA for OntarioApril 14, 2025 | markets.businessinsider.comQuantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for OntarioApril 14, 2025 | globenewswire.comQuantum BioPharma’s licensee expands retail reach with AATAC dealApril 12, 2025 | uk.investing.comQuantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto RicoApril 3, 2025 | globenewswire.comQuantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple SclerosisApril 1, 2025 | globenewswire.comQuantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved TermsMarch 31, 2025 | globenewswire.comQuantum BioPharma reports progress in drug trialsMarch 30, 2025 | uk.investing.comQuantum BioPharma Provides Corporate UpdateMarch 30, 2025 | newsfilecorp.comQuantum BioPharma reports FY24 net loss $14.9M vs. $18.2M last yearMarch 28, 2025 | markets.businessinsider.comOverlooked Stock: QNTMMarch 28, 2025 | youtube.comQuantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going ConcernMarch 28, 2025 | accessnewswire.comQuantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going ConcernMarch 28, 2025 | globenewswire.comQuantum Group announces licensee expands unbuzzd lineupMarch 26, 2025 | markets.businessinsider.comQuantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail SalesMarch 26, 2025 | markets.businessinsider.comQuantum BioPharma Stock Soars After Licensee Celly Nutrition Releases New Format Of Alcohol Detox Product – Retail Shrugs It OffMarch 26, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQNTM, OTLK, AVTX, and CYCC Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$4.78 -0.10 (-2.05%) Closing price 04:00 PM EasternExtended Trading$4.71 -0.07 (-1.38%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Cyclacel Pharmaceuticals NASDAQ:CYCC$0.28 +0.05 (+21.62%) Closing price 04:00 PM EasternExtended Trading$0.28 +0.00 (+1.62%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Outlook Therapeutics NASDAQ:OTLK$1.53 -0.02 (-1.29%) Closing price 04:00 PM EasternExtended Trading$1.53 0.00 (0.00%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Quantum Biopharma NASDAQ:QNTM$7.08 +0.17 (+2.46%) Closing price 04:00 PM EasternExtended Trading$6.76 -0.33 (-4.59%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
